Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #1767: EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer

Naoto Ueno, Tiffany LaFortune, Gabriel Hortobagyi, Anthony Lucci, Balraj Singh, Savitri Krishnamurthy, Francisco Esteva, Mien-Chie Hung and Dongwei Zhang
Naoto Ueno
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany LaFortune
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Hortobagyi
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Lucci
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balraj Singh
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savitri Krishnamurthy
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Esteva
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mien-Chie Hung
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dongwei Zhang
The University of Texas M.D. Anderson Cancer Center, Houston, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Inflammatory breast cancer (IBC) is a rare but aggressive type of advanced breast cancer. Little is known about the etiology of IBC, and effective treatments for IBC are lacking. Recent clinical study showed that Epidermal growth factor receptor (EGFR) overexpression is detected in 30% of IBCs. EGFR-positive IBC is associated with significantly worse 5-year overall survival than EGFR-negative IBC, and EGFR expression is also associated with increased risk of IBC recurrence. In the present study, we determined the impact of blocking the EGFR pathway on IBC characteristics. Two IBC cell lines, SUM149 and KPL-4, which express high level of EGFR were studied. EGFR siRNA knockdown inhibited IBC cell proliferation. The EGFR tyrosine kinase inhibitor erlotinib inhibited proliferation and anchorage-independent growth of IBC cells, and this inhibition was ERK dependent. Erlotinib also inhibited cell motility and invasiveness. Furthermore, erlotinib reversed the mesenchymal phenotype of IBC cells, which may suggest more likely for metastasis, to epithelial phenotype in three-dimensional culture. More importantly, high doses of erlotinib showed significant tumor-growth inhibition in a xenograft model. Mean tumor-growth inhibition was 78% at 4 weeks after 50 mg/kg erlotinib treatment (P < 0.0001) and 95% after 100 mg/kg erlotinib treatment (P < 0.0001). Erlotinib also inhibited lung metastasis, even at a low dose (25 mg/kg). Metastatic tumors in lung were detected in 3 of 7 control mice but none of the 7 erlotinib-treated mice, indicating that erlotinib had activity to inhibit metastatsis of IBC (P < 0.05). Erlotinib-treated tumors had high expression of the epithelial marker E-cadherin and low expression of the mesenchymal marker vimentin compared with untreated tumors, suggesting that erlotinib exerts its antimetastatic activity in IBC by inhibiting epithelial-mesenchymal transition (EMT). Our results indicate that the EGFR pathway is involved in tumor growth and metastasis of IBC. Targeting EGFR through the ERK pathway may represent an effective therapeutic approach to EGFR-expressing IBC.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1767.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #1767: EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #1767: EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer
Naoto Ueno, Tiffany LaFortune, Gabriel Hortobagyi, Anthony Lucci, Balraj Singh, Savitri Krishnamurthy, Francisco Esteva, Mien-Chie Hung and Dongwei Zhang
Cancer Res May 1 2009 (69) (9 Supplement) 1767;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #1767: EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer
Naoto Ueno, Tiffany LaFortune, Gabriel Hortobagyi, Anthony Lucci, Balraj Singh, Savitri Krishnamurthy, Francisco Esteva, Mien-Chie Hung and Dongwei Zhang
Cancer Res May 1 2009 (69) (9 Supplement) 1767;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Kinase Inhibitors 1 -- Poster Presentations - Proffered Abstracts

  • Abstract #1754: Lapatinib enhances TRAIL sensitivity in colorectal cancer cells via a novel EGFR/HER2-independent mechanism involving JNK activation and DR5 up-regulation.
  • Abstract #1752: Preclinical development of a novel, orally active cMet kinase inhibitor with potent antitumor and anti-angiogenic properties
  • Abstract #1766: Study of transforming potential and drug sensitivity of ErbB2 variants identifies lapatinib-resistant kinase domain mutations
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement